Oral mucositis in cancer patients Radiation-
Conditions
Interventions
Cancer
Oral Mucositis
Supportive Care
Cancer
Sponsors
UDON THANI CANCER HOSPITAL
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Current and stable cancer patients under medical and/or radiological treatment program whom able to self-support in terms of standard oral hygiene care and self-provisioning of food-intake under the continuous 5FU under planned radiotherapy at least for 5-6 weeks. 2.Current and stable head and neck cancer patients under medical and/or radiological treatment program whom able to self-support in terms of standard oral hygiene care and self-provisioning of food-intake either pre or post-surgical procedure. 3.Current and stable for non-operative patients diagnosed with CA tongue, CA nasopharynx under medical and/or radiological treatment program whom able to self-support in terms of standard oral hygiene care and self-provisioning of food-intake. 4.Current and stable cancer patients under medical and/or radiological treatment program whom painful oral mucositis is a limiting factor which discouraging the follow-up treatment plan determined by specialist in charge. 5.Hospitalized cancer patients under medical and/or radiological treatment program whom deemed necessary to be included in the study by specialist in charge. 6.Current and stable cancer patients under medical and/or radiological program whom had suffering from oral mucositis with ulcer size/area less than 3cm2 and number of ulcer less than 5 ulcers
Exclusion criteria
Exclusion criteria: 1.Cancer patients whom shall not provide patient-inform consent and is a non-compliance in terms of weekly assessment follow-up visit. 2.Cancer patients whom experience severe gastrointestinal distressed symptoms due to progression of severe mucositis other than oral mucositis and therefore routine management of painful symptoms of oral cavity is not feasible. 3.Advance staging cancer patients whom deemed necessary for exclusion by specialist in charge. 4.Cancer patients with HIV positive. 5.Advance staging cancer patients whom deemed for surgical follow-up. 6.Others cancer patients deem clinically inappropriate by investigators. 7.Non-compliance patients whom topical administration of the pelicles shall be less than 2 weeks. 8.Cancer patients whom shall be developing hypersensitivity and allergic reaction due to the topical application of the pelicles.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The World Health Organization (WHO) oral toxicity scale. At the ends of each of 2 weeks of treatment Objective and subjective symptoms and functional score assessment ,The Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring At the end of each 2 weeks of treatment Clinician’s judgement on anatomical and functional changes of oral mucositis | — |
Secondary
| Measure | Time frame |
|---|---|
| The Oral Mucositis and Daily Questionnaire (OMDQ) scoring At the ends of each of 2 weeks of treatment A subjective patient-reported outcomes scores | — |
Contacts
Public ContactAnan Udombhornprabha
Eastern Asia University
Outcome results
None listed